[Current status of hematopoietic stem cell transplantation for malignant lymphoma].

Satomi Ueda, Shinichiro Okamoto

Research output: Contribution to journalArticle

Abstract

The roles of high-dose chemotherapy/chemo-radiotherapy with either autologous or allogeneic hematopoietic stem cell supports in the treatment lymphoma continue to change. Introduction of molecular targeting agents and other new drugs to the standard chemotherapy have improved the treatment outcome significantly, and hematopoietic stem cell transplantation (HSCT) is not currently used as part of first-line therapy. As opposed to this, autologous HSCT are widely used for the treatment of relapsed or refractory lymphoma. Allogeneic HSCT is also increasingly being considered. However, the outcome of HSCT in relapsed/refractory lymphoma remains unsatisfactory, and a variety of molecular targeting approaches are currently being incorporated in order to improve the outcome of HSCT for lymphoma.

Original languageEnglish
Pages (from-to)478-482
Number of pages5
JournalNihon rinsho. Japanese journal of clinical medicine
Volume72
Issue number3
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Hematopoietic Stem Cell Transplantation
Lymphoma
Drug Therapy
Hematopoietic Stem Cells
Radiotherapy
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

[Current status of hematopoietic stem cell transplantation for malignant lymphoma]. / Ueda, Satomi; Okamoto, Shinichiro.

In: Nihon rinsho. Japanese journal of clinical medicine, Vol. 72, No. 3, 2014, p. 478-482.

Research output: Contribution to journalArticle

@article{b277827c85be45e18841aa10c21bc0d1,
title = "[Current status of hematopoietic stem cell transplantation for malignant lymphoma].",
abstract = "The roles of high-dose chemotherapy/chemo-radiotherapy with either autologous or allogeneic hematopoietic stem cell supports in the treatment lymphoma continue to change. Introduction of molecular targeting agents and other new drugs to the standard chemotherapy have improved the treatment outcome significantly, and hematopoietic stem cell transplantation (HSCT) is not currently used as part of first-line therapy. As opposed to this, autologous HSCT are widely used for the treatment of relapsed or refractory lymphoma. Allogeneic HSCT is also increasingly being considered. However, the outcome of HSCT in relapsed/refractory lymphoma remains unsatisfactory, and a variety of molecular targeting approaches are currently being incorporated in order to improve the outcome of HSCT for lymphoma.",
author = "Satomi Ueda and Shinichiro Okamoto",
year = "2014",
language = "English",
volume = "72",
pages = "478--482",
journal = "Nihon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "3",

}

TY - JOUR

T1 - [Current status of hematopoietic stem cell transplantation for malignant lymphoma].

AU - Ueda, Satomi

AU - Okamoto, Shinichiro

PY - 2014

Y1 - 2014

N2 - The roles of high-dose chemotherapy/chemo-radiotherapy with either autologous or allogeneic hematopoietic stem cell supports in the treatment lymphoma continue to change. Introduction of molecular targeting agents and other new drugs to the standard chemotherapy have improved the treatment outcome significantly, and hematopoietic stem cell transplantation (HSCT) is not currently used as part of first-line therapy. As opposed to this, autologous HSCT are widely used for the treatment of relapsed or refractory lymphoma. Allogeneic HSCT is also increasingly being considered. However, the outcome of HSCT in relapsed/refractory lymphoma remains unsatisfactory, and a variety of molecular targeting approaches are currently being incorporated in order to improve the outcome of HSCT for lymphoma.

AB - The roles of high-dose chemotherapy/chemo-radiotherapy with either autologous or allogeneic hematopoietic stem cell supports in the treatment lymphoma continue to change. Introduction of molecular targeting agents and other new drugs to the standard chemotherapy have improved the treatment outcome significantly, and hematopoietic stem cell transplantation (HSCT) is not currently used as part of first-line therapy. As opposed to this, autologous HSCT are widely used for the treatment of relapsed or refractory lymphoma. Allogeneic HSCT is also increasingly being considered. However, the outcome of HSCT in relapsed/refractory lymphoma remains unsatisfactory, and a variety of molecular targeting approaches are currently being incorporated in order to improve the outcome of HSCT for lymphoma.

UR - http://www.scopus.com/inward/record.url?scp=84899565983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899565983&partnerID=8YFLogxK

M3 - Article

C2 - 24724407

AN - SCOPUS:84899565983

VL - 72

SP - 478

EP - 482

JO - Nihon rinsho. Japanese journal of clinical medicine

JF - Nihon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 3

ER -